Unblocking Part D, MarketView
In specialty pharmacies, some medications may have partially blocked data. Manufacturers, payers, and specialty pharmacies can elect to block this data. When they do, it’s no longer visible to their allied and competitive healthcare stakeholders, like yourself.
CareSet’s Part D Targeting product provides brand teams clarity using Medicare’s unblocked claims data. This allows us to provide our clients with a monthly snapshot of Part D treatments, organized by patient and claims counts at the physician level.
Why is blocking a problem?
Blocking data creates friction for researchers. However, it’s vital to see the whole picture when you research health outcomes and hospitalization rates. This is especially true in the fields of oncology and hematology, where blocking is most common.
One such example occurs in the treatment of multiple myeloma. Many products serve patients with multiple myeloma. Unfortunately, several of the most popular products have blocked data statuses. These products include:
- EMPLICITI (elotuzumab)
- DARZALEX (daratumumab)
- REVLIMID (lenalidomide)
- POMALYST (pomalidomide)
- VELCADE (bortezomib)
- NINLARO (ixazomib)
- BENDEKA (bendamustine HCI)
- KYPROLIS (carfilzomib)
Manufacturers, payers, and specialty pharmacies do have the right to block data. However, sometimes it remains available. One such case is in Medicare’s public reporting dashboards.
Regardless of the therapeutic area, CMS publishes gross prescribing statistics. These include patient counts, patient out-of-pocket costs, and other vital statistics to help measure the utilization of the Part D program.
The figure below identifies several of the top products used to treat multiple myeloma and the popularity of Revlimid and other treatment options.